fagofarma

What fagofarma does

Fagofarma s.r.o. is a Prague-headquartered, privately held Czech biotechnology company founded in 2013 that develops, manufactures, and contract-services bacteriophage-based products. The company operates as a contract research and manufacturing organization (CRO/CDMO) in microbiology, biotechnology, and pharmacy, offering phage isolation and characterization, lysate preparation, custom antibacterial product development, and GMP-compliant manufacturing through its own facilities in Brno (R&D at the JIC INBIT biotechnology incubator) and Roztoky u Prahy (clean-room manufacturing in partnership with MB Pharma), with an additional lab in Ostrava. Its proprietary product portfolio includes TRIOFAG® (a phage cocktail targeting Acinetobacter baumannii, Klebsiella pneumoniae, and Staphylococcus aureus for respiratory infections, advancing toward a March 2026 clinical trial authorization application), DUOFAG® (phage therapy for surgical wound infections), the consumer skincare line FAGOCARE® and FAGOCARE PLUS® for acne-prone skin (sold via fagocare.cz), and NUCLEASE FF (recombinant Serratia marcescens endonuclease).

The firm generates revenue through three streams: contract research and manufacturing services to other public and private research organizations in immunobiology, direct-to-consumer sales of FAGOCARE cosmetic gels via its own e-commerce platform, and non-dilutive Czech public R&D grants (TAČR, Ministry of Industry and Trade, operational programs) funding multiple phage-related projects since 2015. In 2023 Fagofarma obtained SÚKL GMP certification for manufacturing bacteriophages as medicinal substances and evaluated medicinal products, establishing a regulatory moat for pharmaceutical-grade phage manufacturing in the Czech Republic. The company is led by Managing Director Marek Moša, with research operations overseen by Martin Benešík (Brno) and Dominik Dostál (Ostrava), and is currently in preclinical-to-clinical transition with no public equity funding rounds, no named enterprise customers, and a headcount of 1-10.

Name

fagofarma

Legal name

Fagofarma s.r.o.

Website

https://fagofarma.cz

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Fagofarma is a Prague-based Czech CDMO and biotechnology firm developing and manufacturing bacteriophage-based therapeutic products, cosmetics, and enzymes for healthcare institutions, research organizations, and acne-prone consumers, primarily in the Czech Republic.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

Keywords

• Bacteriophage therapy
• Contract pharmaceutical manufacturing
• Biotechnological preparations
• Antimicrobial resistance solutions
• GMP pharmaceutical production

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

1. Contract research services: FAGOFARMA operates as a contract organization providing contract research and manufacturing services in microbiology, biotechnology, and pharmacy. Revenue is generated through R&D service contracts with other research organizations.
2. Contract manufacturing services: Manufacturing services for bacteriophage-based preparations under GMP conditions, including pharmaceutical production according to Good Manufacturing Practice requirements.
3. Cosmetic product sales: Direct sales of FAGOCARE and FAGOCARE PLUS cosmetic products through e-commerce platform (fagocare.cz)

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Fagofarma develops, researches, and manufactures biotechnological preparations based on bacteriophages, including therapeutic medicinal products (TRIOFAG®, DUOFAG®), cosmetic skincare products (FAGOCARE®, FAGOCARE PLUS®), and enzymatic products (NUCLEASE FF). The company also operates as a contract research and manufacturing organization (CRO/CDMO) providing services in microbiology, biotechnology, and pharmacy under SÚKL GMP certification, with research labs in Brno and manufacturing facilities in Roztoky u Prahy.

Product overview

FAGOFARMA is a biotechnology company founded in 2013 specializing in the development, research, and manufacturing of biotechnological preparations based on bacteriophages. The product portfolio consists of therapeutic medicinal products including TRIOFAG® (respiratory tract infections) and DUOFAG® (surgical wound infections), cosmetic skincare products FAGOCARE® and FAGOCARE PLUS® (acne treatment), and industrial enzyme product NUCLEASE FF. The company operates research facilities in Brno and manufacturing laboratories in Roztoky u Prahy, providing contract research and manufacturing services in microbiology, biotechnology, and pharmacy under GMP certification from SÚKL.

Differentiator

Problem solved

Functional benefit

Brands

• FAGOCARE PLUS: Modern cosmetic preparation for problematic skin care containing bacteriophages and endolysins effective against Staphylococcus aureus and Cutibacterium acnes, bacteria associated with acne.
• FAGOCARE
• NUCLEASE FF
• TRIOFAG
• DUOFAG

Quantifiable outcome

• TRIOFAG® demonstrated good tolerability with no adverse effects in Wistar rats in repeated oral toxicity study (GLP, February 2025)
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered core and minor.

• MB PharmacoreStrategic or Co-development PartnerPartnership with MB Pharma for pharmaceutical manufacturing at the Roztoky u Prahy facility. MB Pharma handles GMP-compliant pharmaceutical manufacturing in collaboration with FAGOFARMA's clean room facilities. The partnership enables farmaceutická výroba (pharmaceutical manufacturing) under Good Manufacturing Practice requirements.
• Latvian partners from research and clinical institutionsminorStrategic or Co-development PartnerPartnership established with Latvian partners from research and clinical practice at the Bacteriophage Therapy Workshop held at the Czech Embassy in Riga. Discussions focused on current phage therapy development, personalized treatment possibilities, regulatory framework in EU, and preparation of joint research projects.
• Academic research institutionsminorStrategic or Co-development PartnerThe company maintains professional contact with academic departments at universities in the field of immunobiology, supporting collaborative research and knowledge exchange in bacteriophage applications.
• Public and private research organizations in immunobiologycoreOthersFAGOFARMA functions as a contract organization providing contract research and manufacturing services. Clients and partners include other research organizations (both public and private) in the field of immunobiology.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Intralytix: US-based phage technology company with FDA-approved phage-based food safety products and a clinical pipeline targeting human bacterial infections—closely aligned with Fagofarma's bacteriophage CDMO and product development work.
• Micreos: Dutch biotech developing phage-based endolysin products for human health and food safety; comparable to Fagofarma's consumer FAGOCARE line and its broader endolysin/phage combination strategy.
• BiomX: Israel-based clinical-stage phage therapy company developing phage cocktails for chronic diseases and resistant bacterial infections, comparable in modality and indication overlap to Fagofarma's pipeline.
• Adaptive Phage Therapeutics: US-based clinical-stage phage therapy company developing personalized and targeted phage treatments for antimicrobial-resistant bacterial infections, operating in the same therapeutic space as Fagofarma's pipeline.
• Eligo Bioscience: France-based biotechnology company developing phage-derived precision medicines for microbiome-targeted therapeutics, with similar bacteriophage-based technology platform relevant to Fagofarma's approach.
• PhagoMed Biopharmaceuticals: Austrian biotech developing phage-based therapies for bacterial infections with focus on GMP manufacturing and clinical translation—closely comparable geographically and technically to Fagofarma's European phage platform.
• Locus Biosciences: US-based clinical-stage biotech engineering phage-based antimicrobials (crPhage platform) to target antibiotic-resistant bacteria, paralleling Fagofarma's engineered-phage development work.
• Armata Pharmaceuticals: US-listed clinical-stage bacteriophage therapy company developing targeted phage cocktails for serious bacterial infections including respiratory and wound indications—directly comparable to Fagofarma's TRIOFAG and DUOFAG programs.

Emerging players

• ContraFect: US-based clinical-stage company developing lysin-based antimicrobials (direct lytic agents), closely related to Fagofarma's FAGOCARE PLUS product combining bacteriophages and endolysins for antibacterial activity.

Others

• MB Pharma: Czech pharmaceutical manufacturer and Fagofarma's strategic GMP manufacturing partner at Roztoky u Prahy; relevant peer as it enables Fagofarma's pharmaceutical production and operates in the same Czech contract manufacturing space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/fagofarma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about fagofarma